Table 2.
Baseline demographic and clinical variables and baseline domain scores associated with overall survival
| Variable | Univariatea | Multivariatea | ||
|---|---|---|---|---|
| HR (95 % CI) | P | HR (95 % CI) | P | |
| Baseline characteristics | ||||
| Age <70 y (vs. ≥70 y) | 0.603 (0.349–1.258) | 0.208 | ||
| Sex, male (vs. female) | 0.544 (0.254–1.167) | 0.118 | ||
| HCV infection (vs. other etiology) | 1.138 (0.610–0.122) | 0.684 | ||
| Child Pugh = 5 (vs. ≥6) | 0.419 (0.227–0.812) | 0.009 | ||
| TMN stage III (vs. IV) | 0.695 (0.371–1.304) | 0.257 | ||
| Vascular invasion - (vs. +) | 0.475 (0.204–0.945) | 0.034 | ||
| Tumor size <50 mm (vs. ≥50 mm) | 0.831 (0.441–1.567) | 0.567 | ||
| Previous curative therapy: Yes (vs. No) | 0.255 (0.129–0.504) | <0.001 | 0.235 (0.116–0.477) | <0.001 |
| AFP <100 (vs. ≥100) | 0.893 (0.473–1.686) | 0.726 | ||
| DCP <1000 (vs. ≥1000) | 0.548 (0.280–1.070) | 0.078 | ||
| Initial dose of sorafenib 800 mg (vs. <800 mg) | 1.137 (0.611–2.115) | 0.686 | ||
| Treatment duration ≥5 months (vs. <5) | 0.608 (0.325–1.138) | 0.120 | ||
| HRQOL domain scores ≥40b: | ||||
| Physical functioning | 0.529 (0.278–1.008) | 0.053 | 0.479 (0.245–0.935) | 0.031 |
| Role physical | 0.595 (0.314–1.127) | 0.111 | ||
| Bodily pain | 1.686 (0.772–3.676) | 0.190 | ||
| General health | 1.331 (0.644–2.755) | 0.440 | ||
| Vitality | 0.842 (0.383–1.848) | 0.669 | ||
| Social functioning | 0.833 (0.411–1.684) | 0.610 | ||
| Role emotional | 0.957 (0.473–1.938) | 0.904 | ||
| Mental health | 2.053 (0.893–4.717) | 0.090 | ||
HR hazard ratio, CI confidence interval, HCV hepatitis C virus, TNM tumor-node-metastasis, AFP alpha fetoprotein, DCP des-gamma-carboxy prothrombin, HRQOL health related quality of life
aCox proportional hazards regression analysis
bAll domain scores are relative to scores <40
All variables with P values <0.06 in the univariate analysis were included in the multivariate analysis